Politics, Programming and Possibilities
18 Jan
javax.servlet.ServletContext log: unable to create shared application instanceorg.jruby.rack.RackInitializationException: private method `new’ called for RemembryRave::Robot:Classfrom /base/data/home/apps/remembry/1.339256739153417236/WEB-INF/gems/gems/rack-1.1.0/lib/rack/builder.rb:46:in `initialize’
sun.reflect.NativeMethodAccessorImpl invoke0: TypeError: can’t dup Fixnum/base/data/home/apps/remembry/1.339257167247162572/WEB-INF/gems/gems/rave-0.1.2-java/lib/models/robot.rb:16:in `version’
Warbler::Config.new do |config|config.gems = %w( rave json-jruby rack builder hpricot )config.includes = %w( robot.rb appengine-web.xml )end
robot:name: Remembry Botimage_url:
profile_url: http://remembry.appspot.com/version: ‘9′appcfg:version: 1gems:- hpricot
10 Jan
6 Jan
5 Jan
This is a really neat article about the transition science is taking right now as it reframes the “placebo effect” and its role in health and the search for improvements to the body’s natural (but limited) healing system:
Benedetti often uses the phrase “placebo response” instead of placebo effect. By definition, inert pills have no effect, but under the right conditions they can act as a catalyst for what he calls the body’s “endogenous health care system.” Like any other internal network, the placebo response has limits. It can ease the discomfort of chemotherapy, but it won’t stop the growth of tumors. It also works in reverse to produce the placebo’s evil twin, the nocebo effect. For example, men taking a commonly prescribed prostate drug who were informed that the medication may cause sexual dysfunction were twice as likely to become impotent.
In a study last year, Harvard Medical School researcher Ted Kaptchuk devised a clever strategy for testing his volunteers’ response to varying levels of therapeutic ritual. The study focused on irritable bowel syndrome, a painful disorder that costs more than $40 billion a year worldwide to treat. First the volunteers were placed randomly in one of three groups. One group was simply put on a waiting list; researchers know that some patients get better just because they sign up for a trial. Another group received placebo treatment from a clinician who declined to engage in small talk. Volunteers in the third group got the same sham treatment from a clinician who asked them questions about symptoms, outlined the causes of IBS, and displayed optimism about their condition.Not surprisingly, the health of those in the third group improved most. In fact, just by participating in the trial, volunteers in this high-interaction group got as much relief as did people taking the two leading prescription drugs for IBS. And the benefits of their bogus treatment persisted for weeks afterward, contrary to the belief—widespread in the pharmaceutical industry—that the placebo response is short-lived.